Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BICYCLE THERAPEUTICS PLC Director's Dealing 2019

May 31, 2019

32777_dirs_2019-05-31_6e075a14-ba72-4a88-8b2a-3b4d9d560da3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BICYCLE THERAPEUTICS plc (BCYC)
CIK: 0001761612
Period of Report: 2019-05-28

Reporting Person: Cambridge Innovation Capital (Jersey) Ltd (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-05-28 Ordinary Shares C 1081823 Acquired 1081823 Direct
2019-05-28 Ordinary Shares X 125587 Acquired 1207410 Direct
2019-05-28 Ordinary Shares C 229741 Acquired 1437151 Direct
2019-05-29 Ordinary Shares P 314286 $14 Acquired 1751437 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-05-28 Series B1 Preferred Shares $ C 1081823 Disposed Ordinary Shares (1081823) Direct
2019-05-28 Series B1 Preferred Shares Warrants $ X 125587 Disposed Ordinary Shares (125587) Direct
2019-05-28 Series B2 Preferred Shares $ C 229741 Disposed Ordinary Shares (229741) Direct

Footnotes

F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2: Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.